Sign inROSETTA Lung-107 data show a 36.7% response rate and 6.9-month median PFS for pumitamig plus docetaxel in previously treated NSCLC, presented at ESMO 2026.
SEC filing (3)
Low-dose budoprutug showed B-cell depletion and immunologic remission at Week 12, with additional Phase 2 data expected in 2027.
SEC filing
Supernus Pharmaceuticals ended its uncommitted revolving credit facility with UBS Bank USA on October 20, 2026, citing its pending combination with Indivior Pharmaceuticals.
SEC filing
GSK said mocertatug rezetecan produced a 62% confirmed response rate and 12.2-month median duration of response in the BEHOLD-1 trial, with five phase III studies now underway.
SEC filing
The company said the trial met its safety endpoint, with one second-line patient reaching 16.39 months progression-free and over 20.7 months overall survival.
SEC filing
Senti shifted its operating business to Parent while keeping rights to Rett Syndrome and TIL programs, with shareholders eligible for up to $60 million in milestone-based CVRs tied to SENTI-202.
SEC filing
The approval covers metastatic prostate cancer patients with HRR gene mutations who have not yet received or are still responding to androgen pathway modulation.
FDA, Drugs@FDA (2)
The company said a 6 mg/kg dose produced a 44.8% response rate in pretreated colorectal cancer patients, with data presented at ESMO Congress 2026.
SEC filing
The company said the charge from its completed Actio acquisition will cut roughly $11.00 from both GAAP and non-GAAP EPS in the third quarter of 2026.
SEC filing
The San Mateo biotechnology company reported $75.1 million sold toward an offering that could raise up to $80 million, per a Form D filed October 26, 2026.
SEC filing
Acumen Pharmaceuticals said it expects topline results from its Phase 2 sabirnetug trial in November 2026 and reported $78.6 million in cash as of September 30, 2026.
SEC filing
Preliminary, unaudited figures show 792 units sold to U.S. wholesalers in the quarter ended September 30, 2026, up from 360 in the prior quarter, with institutional adoption also rising.
SEC filing (2)
The companies announced a definitive strategic agreement on October 26, 2026, to combine manufacturing, clinical, and commercial resources for regenerative medicine, aesthetics, wellness, and longevity markets.
SEC filing
Neogen Corporation filed an amended report to disclose that shareholders approved an updated omnibus equity incentive plan at the company's October 1, 2026 annual meeting.
SEC filing
Seres disclosed in an SEC filing that Chief Financial Officer Marella Thorell will resign effective November 15, 2026, with a transition role expected to follow.
SEC filing
The October 26, 2026 filing registers resale shares tied to the $50 million Roth Principal Investments purchase agreement, as Traws stock closed at $0.34.
SEC filing (2)
CEO Giorgio Saumat steps in to handle the company's finance and accounting duties temporarily while a permanent replacement is sought.
SEC filing
The board elevated interim CEO Sushma Shivaswamy and longtime clinical staffer Jan-Paul Simard to share the chief executive role, per an 8-K filed October 26, 2026.
SEC filing
The agency cleared a priority-reviewed supplemental biologics license application for the insulin icodec injection on October 23, 2026.
Drugs@FDA
The agency cleared a sixth supplemental application for the intravenous iron drug on October 23, 2026.
Drugs@FDA
Seattle biotech says interim results show durable disease control and tumor responses across three dose cohorts in neuroendocrine tumor patients, with Phase 3 prep targeted for year-end 2026.
SEC filing
Bolt will advance Prana's lead bispecific antibody PRA-216 across four Phase 2 studies, backed by financing meant to fund operations into 2028.
SEC filing
Tango plans a Phase 3 trial starting in the first half of 2027 after FDA discussions on the PRMT5 inhibitor paired with Revolution Medicines' RAS(ON) drug.
SEC filing
The companies said updated data show sustained APRIL suppression and a roughly 70% drop in a key pathogenic marker, supporting quarterly dosing ahead of a 2027 Phase 3 trial.
SEC filing
The company said the ASSIST-SSc trial results support the drug's safety and tolerability in the rare disease population.
SEC filing
The company's October 23, 2026 shareholder letter cited a $2.5 million liability total, a $3.7 million nine-month operating loss, and plans to spin GridFeed into a standalone subsidiary.
SEC filing
The agency cleared a priority-reviewed supplemental application for risankizumab-rzaa on October 23, 2026, though the specific new use was not detailed in the record.
Drugs@FDA
The company said the terminated Phase 3 trial's partial data support continued development as the FDA has lifted its clinical hold on ARD-101.
SEC filing
Ionis partner Roche said sefaxersen lowered proteinuria 43.1% versus placebo at 37 weeks in the Phase 3 IMAgINATION study, with safety consistent with Phase 2.
SEC filing
NeuroThera Labs secured European regulatory sign-off on trial material, moving its SCI-110 Phase IIb study for Tourette Syndrome closer to patient enrollment.
SEC filing
Nasdaq granted Citius Oncology additional time to meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
SEC filing
Nasdaq told Medicus Pharma on October 23, 2026 that its shares had regained compliance with the $1.00 minimum bid price rule, closing the matter.
SEC filing
The Carlsbad, California company reported $110,000 raised so far from two investors in an equity offering under Rule 506(b).
SEC filing
The company's board amended its shareholder rights agreement with Computershare, pushing the final expiration date to October 27, 2027.
SEC filing
SEC 6-K filing shows the drugmaker's Q2 FY27 revenue and profit both declined from a year earlier, with a Semaglutide inventory charge and a CAR-T asset sale noted.
SEC filing
The Seattle biotech's amended rights plan also resets the purchase price to $14.56 per one one-thousandth of a preferred share.
SEC filing
The filing details a 30-patient hospital study, a chronic-disease trial, and plans for a possible sNDA filing in 2027 with a requested priority review.
SEC filing
The clinical-stage degrader company will list on Nasdaq as "LYCA" with shares expected to deliver October 26, 2026.
SEC filing
Nasdaq's Office of General Counsel confirmed compliance on October 22, 2026, closing the matter and cancelling the November 10 Hearings Panel session.
SEC filing (2)
The company has until April 19, 2027 to bring its share price back above the $1.00 minimum bid threshold.
SEC filing
The company filed a prospectus supplement reducing the amount it can sell under its ATM agreement with H.C. Wainwright to roughly $2,006,769.
SEC filing
The company sold 16,428,572 shares at a $17.50 public offering price after underwriters fully exercised their option to buy additional stock.
SEC filing
Zymeworks will get $55 million upfront plus up to $758 million in milestones and tiered royalties as Roche takes over global rights to the trispecific T cell engager.
SEC filing
The company priced an 11.34 million ADS private placement at $22.04 per share and released a corporate presentation with fresh DLL3 ADC trial results.
SEC filing
Elizabeth H.Z. Thompson's departure as head of research and development took effect October 23, 2026, following an April retirement notice.
SEC filing
The board approved salary increases for Pardeep Nijhawan, Michael Brooks and Peter Weiler, retroactive to July 1, 2026.
SEC filing